Yan Xu

Yan Xu

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
FLFan Li
Fan Li
YXYan Xu
Yan Xu
BLBovey Liu
Bovey Liu
PSPankaj Kumar Singh
Pankaj Kumar Singh
WZWei Zhao
Wei Zhao
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Purpose: Esophageal cancer (EC) is a lethal disease that is often resistant to therapy. Alterations of YAP1 and CDK6 are frequent in EC. Deregulation of both molecules may be responsible for therapy resistance. Experimental Design: Expression of YAP1 and CDK6 were examined in EC cells and tissues using immunoblotting and immunohistochemistry. YAP1 expression was induced in EC cells to examine YAP1-mediated CDK6 activation and its association with radiation resistance. Pharmacological and genetic inhibitions of YAP1 and CDK6 were performed to dissect the mechanisms and assess the antitumor effects in vitro and in vivo. Results: YAP1 expression was positively associated with CDK6 expression in resistant EC tissues and cell lines. YAP1 overexpression upregulated CDK6 expression, transcription, and promoted radiation resistance; whereas treatment with the YAP1 inhibitor, CA3, strongly suppressed YAP1 and CDK6 overexpression, reduced Rb phosphorylation as well as sensitized radiation resistant/YAP1high EC cells to irradiation. CDK4/6 inhibitor, LEE011, and knock down of CDK6 inhibited expression of YAP1 and sensitized resistant EC cells to irradiation indicating a positive feed-forward regulation of YAP1 by CDK6. Additionally, suppression of both the YAP1 and CDK6 pathways by the combination of CA3 and LEE011 significantly reduced EC cell growth, CSC population (ALDH1+ and CD133+), sensitized cells to irradiation and showed a strong anti-tumor effect in vivo against radiation resistant EC cells. Conclusions: Our results document that a positive crosstalk of YAP1 and CDK6 confers radiation resistance to EC cells. Targeting both YAP1 and CDK6 pathways could be novel therapeutic strategies to overcome resistance in EC.

1 March 2020 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
Shumei SongShumei Song
Shumei Song
ZWZhenning Wang
Zhenning Wang
YLYuan Li
Yuan Li
LMLang Ma
Lang Ma
JJJiankang Jin
Jiankang Jin
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Despite established functions of PPARδ in lipid metabolism and tumorigenesis, the mechanisms underlying its role in gastric cancer are undefined. Here, we demonstrate that SOX9 was dramatically induced by stably expressing PPARδ and by its agonist GW501516 in human gastric cancer cell lines. PPARδ knockdown in patient-derived gastric cancer cells dramatically reduced SOX9 expression and transcriptional activity, with corresponding decreases in invasion and tumor sphere formation. Mechanistically, PPARδ induced SOX9 transcription through direct interaction with and activation of the Hippo coactivator YAP1. PPARδ–YAP1 interaction occurred via the C-terminal domain of YAP1, and both TEAD- and PPARE-binding sites were required for SOX9 induction. Notably, CRISPR/Cas9-mediated genetic ablation of YAP1 or SOX9 abolished PPARδ-mediated oncogenic functions. Finally, expression of PPARδ, YAP1, and SOX9 were significantly correlated with each other and with poor survival in a large cohort of human gastric cancer tissues. Thus, these findings elucidate a novel mechanism by which PPARδ promotes gastric tumorigenesis through interaction with YAP1 and highlights the PPARδ/YAP1/SOX9 axis as a novel therapeutic target in human gastric cancer.Implications: Our discovery of a new model supports a distinct paradigm for PPARδ and a crucial oncogenic function of PPARδ in gastric cancer through convergence on YAP1/TEAD signaling. Therefore, PPARδ/YAP1/SOX9 axis could be a novel therapeutic target that can be translated into clinics.

15 October 2020 in Cancers
Verified
Journal Article
Open access
PDF file
YLYuan Li
Yuan Li
Shumei SongShumei Song
Shumei Song
MPMelissa Pool Pizzi
Melissa Pool Pizzi
Guangchun HanGuangchun Han
Guangchun Han
ASAiling W. Scott
Ailing W. Scott
Jaffer AjaniJaffer Ajani
Jaffer Ajani
Gastric adenocarcinoma (GAC) is inherently resistant or becomes resistant to therapy, leading to a poor prognosis. Mounting evidence suggests that lncRNAs can be used as predictive markers and therapeutic targets in the right context. In this study, we determined the role of lncRNA-PVT1 in GAC along with the value of inhibition of PVT1 using antisense oligos (ASOs). RNA scope in situ hybridization was used to analyze PVT1 expression in tumor tissue microarrays (TMAs) of GAC and paired normal tissues from 792 patients. Functional experiments, including colony formation and invasion assays, were performed to evaluate the effects of PVT1 ASO inhibition of PVT1 in vitro; patient-derived xenograft models were used to evaluate the anti-tumor effects of PVT1 ASOs in vivo. LncRNA-PVT1 was upregulated in GACs compared to the matched adjacent normal tissues in the TMA. LncRNA PVT1 expression was positively correlated with larger tumor size, deeper wall invasion, lymph node metastases, and short survival duration. Inhibition of PVT1 using PVT1 ASOs significantly suppressed tumor cell growth and invasion in vitro and in vivo. PVT1 expression was highly associated with poor prognosis in GAC patients and targeting PVT1 using PVT1 ASOs was effective at curtailing tumor cell growth in vitro and in vivo. Thus, PVT1 is a poor prognosticator as well as therapeutic target. Targeting PVT1 using PVT1 ASOs provides a novel therapeutic strategy for GAC.

31 March 2023
Verified
Other
Open access
FLFan Li
Fan Li
YXYan Xu
Yan Xu
BLBovey Liu
Bovey Liu
PSPankaj Kumar Singh
Pankaj Kumar Singh
WZWei Zhao
Wei Zhao
JAJaffer A. Ajani
Jaffer A. Ajani
Purpose:Esophageal cancer is a lethal disease that is often resistant to therapy. Alterations of YAP1 and CDK6 are frequent in esophageal cancer. Deregulation of both molecules may be responsible for therapy resistance.Experimental Design:Expressions of YAP1 and CDK6 were examined in esophageal cancer cells and tissues using immunoblotting and immunohistochemistry. YAP1 expression was induced in esophageal cancer cells to examine YAP1-mediated CDK6 activation and its association with radiation resistance. Pharmacologic and genetic inhibitions of YAP1 and CDK6 were performed to dissect the mechanisms and assess the antitumor effects in vitro and in vivo.Results:YAP1 expression was positively associated with CDK6 expression in resistant esophageal cancer tissues and cell lines. YAP1 overexpression upregulated CDK6 expression and transcription, and promoted radiation resistance, whereas treatment with the YAP1 inhibitor, CA3, strongly suppressed YAP1 and CDK6 overexpression, reduced Rb phosphorylation, as well as sensitized radiation-resistant/YAP1high esophageal cancer cells to irradiation. CDK4/6 inhibitor, LEE011, and knock down of CDK6 dramatically inhibited expression of YAP1 and sensitized resistant esophageal cancer cells to irradiation indicating a positive feed-forward regulation of YAP1 by CDK6. In addition, suppression of both the YAP1 and CDK6 pathways by the combination of CA3 and LEE011 significantly reduced esophageal cancer cell growth and cancer stem cell population (ALDH1+ and CD133+), sensitized cells to irradiation, and showed a strong antitumor effect in vivo against radiation-resistant esophageal cancer cells.Conclusions:Our results document that a positive crosstalk between the YAP1 and CDK6 pathways plays an important role in conferring radiation resistance to esophageal cancer cells. Targeting both YAP1 and CDK6 pathways could be a novel therapeutic strategy to overcome resistance in esophageal cancer.